Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: Analysis of the controlled rosuvastatin multinational trial in heart failure trial (CORONA)

European Journal of Heart Failure

Volumn 12, Issue 7, 2010, Pages 698-705

  Inglis, Sally C ^a,b   McMurray, John J V ^a   Böhm, Michael ^c   Schaufelberger, Maria ^d   Van Veldhuisen, Dirk J ^e   Lindberg, Magnus ^f   Dunselman, Peter ^e,g   Hjalmarson, Åke ^h   Kjekshus, John ⁱ   Waagstein, Finn ^h   Wedel, Hans ^j   Wikstrand, John ^h  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c SAARLAND UNIVERSITY   (Germany)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f ASTRAZENECA R AND D   (Sweden)

^g AMPHIA HOSPITAL   (Netherlands)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

more..

Author keywords

Atherosclerosis; Chronic heart failure; Outcomes; Peripheral artery disease

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APOLIPOPROTEIN A1; C REACTIVE PROTEIN; CREATINE KINASE; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PLACEBO; ROSUVASTATIN; THYROTROPIN; TRIACYLGLYCEROL;

ABDOMINAL AORTA ANEURYSM; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART INFARCTION; HOSPITALIZATION; HUMAN; INTERMITTENT CLAUDICATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; CAUSE OF DEATH; CONTROLLED STUDY; HEART FAILURE, SYSTOLIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CAUSE OF DEATH; FEMALE; HEART FAILURE, SYSTOLIC; HOSPITALIZATION; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 77954930623     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq070     Document Type: Article

References (30)

1. Cassar K. Intermittent claudication. BMJ 2006;333:1002-1005.
2. Lyden SP, Joseph D. The clinical presentation of peripheral arterial disease and guidance for early recognition. Cleve Clin J Med 2006;73:S15-S21.
3. Bertomeu V, Morillas P, Gonzalez-Juanatey JR, Quiles J, Guindo J, Soria F, Llacer A, Lekuona I, Mazón B, Mart́?n-Luengo C, Rodriguez-Padial L, on behalf of The Prevalence of Peripheral Arterial Disease in Patients with Acute Coronary Syndrome (PAMISCA) Investigators. Prevalence and prognostic influence of peripheral arterial disease in patients ≥40 years old admitted into hospital following an acute coronary event. Eur J Vasc Endovasc Surg 2008;36:189-196.
4. Cotter G, Cannon CP, McCabe CH, Michowitz Y, Kaluski E, Charlesworth A, Milo O, Bentley J, Blatt A, Krakover R, Zimlichman R, Reisin L, Marmor A, Lewis B, Vered Z, Caspi A, Braunwald E. Prior peripheral arterial disease and cer-ebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofi-ban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J 2003;145:622-627.
5. Criqui M, Denenberg J. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med 1998;3:241-245.
6. Makowsky MJ, McAlister FA, Galbraith PD, Southern DA, Ghali WA, Knudtson ML, Tsuyuki RT. Lower extremity peripheral arterial disease in individuals with coronary artery disease: prognostic importance, care gaps, and impact of therapy. Am Heart J 2008;155:348-355.
7. Martinez-Selles M, Barrio J, Hortal J, Ruiz M, Bueno H. Prevalence of peripheral arterial disease and prior stroke in octogenarians with symptomatic severe aortic stenosis or severe coronary artery disease: influence in management and outcome. Int Angiol 2007;26:33-37.
8. Nakata S, Yokoi Y, Matsumoto R, Shirai N, Otsuka R, Sugioka K, Yoshitani H, Ehara S, Kataoka T, Yoshiyama M. Long-term cardiovascular outcomes following ischaemic heart disease in patients with and without peripheral vascular disease. Osaka City Mel J 2008;54:21-30.
9. Shammas N. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag 2007;3:229-234.
10. Fowkes FGR. Epidemiological research on peripheral vascular disease. J Clin Epidemiol 2001;54:863-868.
11. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, McMurray J, Waagstein F, Wedel H, Wessman P, Wikstrand J, on behalf of the CORONA Study Group. A statin in the treatment of heart failure? Controlled Rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005;7:1059-1069.
12. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JGF, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJV, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, on behalf of the CORONA Study Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261.
13. Wedel H, McMurray JJV, Lindberg M, Wikstrand J, Cleland JGF, Cornel JH, Dunselman P, Hjalmarson A, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F, on behalf of the CORONA Study Group. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 2009;11:281-291.
14. Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman NS, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC Jr, Pollack CV Jr, Gibler WB, Ohman EM, Roe MT, for the CRUSADE Investigators. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J 2009;30:1195-1202.
15. Chiu JH, Topol EJ, Whitlow PL, Hsu AP, Tuzcu EM, Franco I, Moliterno DJ. Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization. Am J Cardiol 2003;92:582-583.
16. Froehlich JB, Mukherjee D, Avezum A, Budaj A, Kline-Rogers EM, López-Sendón J, Allegrone J, Eagle KA, Mehta RH, Goldberg RJ. Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Am Heart J 2006;151: 1123-1128.
17. Saw J, Bhatt DL, Moliterno DJ, Brener SJ, Steinhubl SR, Lincoff AM, Tcheng JE, Harrington RA, Simoons M, Hu T, Sheikh MA, Kereiakes DJ, Topol EJ. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol 2006;48:1567-1572.
18. Poredos? P, Jug B, for the Study Group. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology 2007;58:309-315.
19. Ahmed MI, Aronow WS, Criqui MH, Aban I, Love TE, Eichhorn EJ, Ahmed A. Effects of peripheral arterial disease on outcomes in advanced chronic systolic heart failure: a propensity-matched study. Circ Heart Fail 2010;3:118-124.
20. de Silva R, Loh H, Rigby AS, Nikitin NP, Witte KKA, Goode K, Bhandari S, Nicholson A, Clark AL, Cleland JGF. Epidemiology, associated factors, and prognostic outcomes of renal artery stenosis in chronic heart failure assessed by magnetic resonance angiography. Am J Cardiol 2007;100:273-279.
21. de Silva R, Nikitin NP, Bhandari S, Nicholson A, Clark AL, Cleland JGF. Atherosclerotic renovascular disease in chronic heart failure: should we intervene? Eur Heart J 2005;26:1596-1605.
22. Cleland JGF, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA. The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157-164.
23. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-1239.
24. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JGF, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR, for the WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial. Circ 2009;119:1616-1624.
25. Velavan P, Huan Loh P, Clark A, Cleland JG. The cholesterol paradox in heart failure. Congest Heart Fail 2007;13:336-341.
26. Meune C, Mahé I, Mourad JJ, Cohen-Solal A, Levy B, Kevorkian JP, Jondeau G, Habib A, Lebret M, Knellwolf AL, Simoneau G, Caulin C, Bergmann JF. Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. Eur J Heart Fail 2003;5:271-279.
27. Witte KK, Clark AL. The effect of aspirin on the ventilatory response to exercise in chronic heart failure. Eur J Heart Fail 2004;6:745-748.
28. Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M, GISSI-HF Investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004;6:365-641.
29. The WASH study Steering Committee and Investigators. The WASH Study (Warfarin/Aspirin Study in Heart failure) rationale, design and end-points. Eur J Heart Fail 1999;1:95-99.
30. Bennett PC, Silverman S, Gill PS, Lip GYH. Ethnicity and peripheral artery disease. Q J Med 2008;102:3-16.